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Summary Spinal cord compression (SCC) is a relatively uncommon but frequently disabling complication of
metastatic breast cancer. We have conducted this retrospective study of 70 patients with SCC secondary to
breast cancer with the aims of determining risk factors for its development and predictors of outcome. Median
age at diagnosis of breast cancer was 51 years with median time to SCC 42 months. All patients had
radiological evidence of bone metastases at the time of SCC, and only five were not known to have bone
metastases prior to SCC. The most frequent symptom of SCC was motor weakness (96%) followed by pain
(94%), sensory disturbance (79%) and sphincter disturbance (61%). Ninety-one percent of patients had at
least one symptom for more than a week.
Radiotherapy (RT) was given as primary treatment in 43 cases, whilst 21 had decompressive surgery and
seven of these went onto have postoperative radiotherapy. Six patients were deemed too unwell for either
modality. Following treatment, 96% of those who were ambulant before therapy maintained the ability to
walk. In those unable to walk, 45% regained ambulation, with RT and surgery being equally effective.
Median survival following SCC was 4 months, with no significant difference between those treated by RT or
surgery. The most important predictor of survival was ability to walk after treatment, followed by time from
diagnosis of breast cancer to SCC.
We conclude that the majority of patients have warning symptoms of SCC and that nearly all will have
evidence of spinal bone metastases before compression occurs. The results suggest that earlier diagnosis and
intervention could improve outcome. There was no evidence of benefit from surgery over radiotherapy as
primary treatment, survival in both treatment groups being poor.
Spinal cord compression is a relatively uncommon complica-
tion of metastatic breast cancer. Previous studies have sug-
gested an incidence of 3% among breast cancer patients with
first relapse of disease in bone (Coleman & Rubens, 1987)
and between 5% and 10% in autopsy series of patients with
various primary sites (Barron et al., 1959; Klein et al., 1991;
Lewis et al., 1986). Since metastatic breast cancer is a rela-
tively common disease causing approximately 15,000 deaths
each year in the UK, a 5% incidence would indicate that
about 750 women will develop this complication annually.
Unless treated effectively, spinal cord compression leads to
permanent paralysis, incontinence and sensory loss, and in-
creases the suffering experienced by patients with advanced
cancer. It may cause loss of independence and prolonged
hospitalisation (Gilbert et al., 1978; Richards et al., 1993).
We have conducted a retrospective analysis of spinal cord
compression among women treated for advanced breast
cancer in the Clinical Oncology Unit at Guy's Hospital. The
aims of the study were to look for risk factors which might
assist in the early detection ofcord compression and to assess
determinants of functional outcome and survival following
cord compression.
Patients and methods
Patients with breast cancer who had developed spinal cord or
Cauda Equina compression between January 1976 and Decem-
ber 1990 were identified from a computerised database. In-
formation concerning characteristics at initial diagnosis of
breast cancer, disease free interval, time to development of
cord compression and survival after cord compression was
also retrieved from the database.
The case notes of all patients recorded as having cord
compression were reviewed to verify the diagnosis and to
ascertain the nature and duration of symptoms and clinical
signs present at the time of cord compression. The diagnosis
of cord compression was accepted if there were either sensory
symptoms, weakness, sphincter disturbance or a combination
of these features in association with demonstrable neurolog-
ical signs and at least one abnormal radiological investigation
corresponding to the site of compression - plain radiograph,
radionuclide bone scan, myelogram, computerised tomo-
graphy or magnetic resonance imaging (MRI). Patients with
neurological deficits due to nerve root compression, limb
girdle plexopathy, peripheral neuropathy or epidural com-
pression proven to be due to non-metastatic phenomena were
excluded.
Details of radiotherapy treatment given to the spine before
the onset of neurological deficit were also obtained from the
case notes as were the numbers of patients who developed
cord compression during radiotherapy being given for pain
control. Treatment for cord compression varied according to
individual circumstances. In general, surgical decompression
was preferred if the patient was otherwise fit, if the signs
were rapidly progressive and if the site had previously been
irradiated, whereas radiotherapy was given to patients with
more slowly progressive symptoms or signs at previously
non-irradiated site (Coleman & Rubens, 1987). Information
related to functional outcome following treatment for cord
compression was also recorded.
Statistical analysis
Relapse free interval was calculated from the date of histo-
logical diagnosis of breast cancer to the date of first recur-
rence. The date of the first abnormal radionuclide bone scan
or plain radiograph was taken as the time of onset of bone
metastases. Survival following cord compression was calcul-
ated from the time of investigation used to confirm the
diagnosis until death or last follow up. The survival of
different subgroups of patients was compared using the log-
rank method.
Results
Seventy cases of cord compression were identified, two of
whom were alive at the time of analysis. The median age at
first diagnosis was 51 years (range 30-80 years). Other char-
acteristics at the time of initial diagnosis of breast cancer are
shown in Table I, and these are also shown for the denomin-
ator population of all patients seen in the unit over this
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period as well as those developing metastatic disease during
that time. The median interval between diagnosis of breast
cancer and development of cord compression was 42 months
(range 16 days-25 years), with a median age at onset of
compression of 54 years. All patients had radiological evi-
dence of bone metastases at the time of cord compression. In
65 patients (93%) bone metastases at one or more skeletal
sites had been proven radiologically prior to the onset of
neurological deficit, 46 of whom had spinal metastases. The
median time from diagnosis of breast cancer to the develop-
ment of bone metastases was 28 months (range 0-25 years)
and to SCC was 42 months (0-25 years). Median time from
first bone metastasis to cord compression was 11 months
(0-7.5 years).
The commonest symptom at the time of SCC was motor
weakness (96%) followed by pain (94%), sensory disturbance
(79%) and sphincter disturbance (61%). Prior to treatment,
31 (45%) were ambulant. The duration for which these
symptoms had been present is shown in Table II. In only two
patients was pain the only symptom; the other 68 all had at
least one neurological symptom and in 65% this had been
present for more than 1 week. All patients had one or more
abnormal neurological signs.
In 49 patients the diagnosis was confirmed by myelo-
graphy, CT or MRI. For the remainder the diagnosis was
based on clinical features in association with spinal radio-
graphy and radionuclide bone scanning or by post mortem
findings. The thoracic spine was the commonest site of
clinically dominant compression (50 cases, 71%), followed by
the lumbosacral region (20%) and cervical spine (9%). There
was radiological evidence of multiple levels of compression in
26 cases (37%).
Table I Characteristics at diagnosis of primary breast cancer
Spinal cord All Metastatic
compression patientsa diseaseb
n % % %
Premenopausal 38 (54) 45 52
Postmenopausal 32 (46) 55 48
Stage
I/II Operable 49 (70) 83 73
III Locally advanced 13 (19) 12 17
IV Metastatic 8 (11) 5 10
Histology
Infiltrating ductal 46 (66) 76 76
Infiltrating lobular 7 (10) 11 10
Other/Not specified 17 (24) 13 14
Axillary nodes: (Operable patients only)
Negative 18 (36) 53 36
1 -3 positive 13 (26) 29 33
>3 19 (38) 18 31
Receptor status:
ER positive 29/37 (78) 74 70
PR positive 12/31 (39) 55 49
aCharacteristics at diagnosis for all patients seen in the Unit over the
15 year period of the study. bCharacteristics of diagnosis for patients
who developed metastatic disease (any site) over the study period.
Table II Symptoms at diagnosis of spinal cord compression
Duration
<I week >I week
n (%) (%) (%)
A. Pain 62/66 (94) 15 85
B. Weakness 66/69 (96) 49 51
C. Sensory loss 42/53 (79) 50 50
D. Sphincter dysfunction 33/54 (61) 84 16
E. B, C or D 68/70 (97) 35 65
F. At least one symptom 70/70 (100) 9 91
Note: The denominator in eachcategory gives the number ofpatients
for whom information could be accurately ascertained from the case
notes. Percentages relate to the proportion of patients for whom
information was available.
Radiotherapy had been given to the site of cord compres-
sion before the onset of neurological deficit in 31 cases
(44%). A further 11 patients (16%) developed compression
whilst receiving radiotherapy for painful spinal metastases.
All patients received dexamethasone at the time of diagnosis
of cord compression, at a dose of 8-16 mg per day. Addi-
tional treatment given for cord compression is shown in
Table III. Radiotherapy alone was given in 43 cases, the
majority of whom (70%) had not previously received radio-
therapy to this site. Surgical decompression was used in 21
cases, seven of whom had postoperative radiotherapy. Of the
14 patients who did not receive adjuvant irradiation, ten had
already had radiotherapy to the site of SCC, and further
treatment was not considered possible. In six cases neither
surgical decompression nor radiotherapy was deemed appro-
priate in view of the patient's general condition.
Functional outcome and symptomatic benefit following
specific treatment for SCC are summarised in Table IV.
Twenty-three (40%) of 58 retrospectively assessable patients
were able to walk before receiving either radiotherapy or
surgery. Twenty-two of these 23 (96%) maintained the ability
Table III Treatment chosen for spinal cord compression
Prior RT No prior RT
Treatment n To site ofSCC
Radiotherapy alone 43 13 (30%) 30 (70%)
Surgery±radiotherapy 21 13 (62%) 8 (38%)
Supportive treatment alone 6 5 (83%) 1 (16%)
Total 70 31 (44%) 39 (56%)
Table IV Functional outcome
All
patients RT alone Surg± RT
A. Ambulation
1. Walking pre-treatment 23 16 7
Ability maintained 22 (96) 16 (100) 6 (86)
Ability lost 1 (4) 0 (0) 1 (14)
2. Not walking pre-treatment 29 17 12
Ability regained 13 (45) 8 (47) 5 (42)
Ability lost 16 (55) 9 (53) 7 (58)
3. Data inadequate 12 10 2
B. Pain
1. Present pre-treatment 56 37 19
Outcome- Better 29 (72) 17 (71) 12 (75)
- Same 10 (25) 6 (25) 4 (25)
- Worse 1 (3) 1 (4) 0 (0)
- Unknown 16 13 3
2. Absent pre-treatment 4 3 1
Outcome - Remained pain
free 4 3 1
3. Data inadequate 4 3 1
C. Sphincter control
1. Abnormal pre-treatment 30 18 12
Outcome- Better 27 (63) 10 (62) 7 (64)
- Same 7 (26) 3 (19) 4 (36)
-Worse 3 (11) 3 (19) 0 (0)
-Unknown 3 2 1
2. Normal pre-treatment 21 15 6
Outcome -Remained normal 19 (90) 14 (93) 5 (83)
- Became abnormal 2 (90) 1 (7) 1 (17)
3. Data inadequate 13 10 3
D. Sensory symptoms
1. Present pre-treatment 38 23 15
Outcome - Better 19 (59) 11 (55) 8 (67)
-Same 9 (28) 6 (30) 3 (25)
-Worse 4 (13) 3 (15) 1 (8)
- Unknown 6 3 3
2. Absent pre-treatment 12 9 3
Outcome - Remained absent 11 (92) 8 (89) 3 (100)
-Developed post
treatment 1 (8) 1 (11) 0 (0)
3. Data inadequate 14 11 3
Figures in parentheses are percentages. The six patients who received
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to walk following treatment. Thirteen of 29 (45%) patients
who were unable to walk regained this ability following
specific treatment. The six patients who received supportive
treatment only were all unable to walk. In the large majority
of cases sphincter control, pain and sensory symptoms either
improved or remained stable following treatment (Table IV).
No differences in functional outcome were observed between
the treatment groups.
Median survival following the diagnosis of SCC was 4
months (range 0-56 months). Two patients were alive at the
time of analysis, both being relatively long term survivors
post SCC (33 months and 56 months). No difference in
survival was observed between those who underwent surgery
with or without radiotherapy and those who received radio-
therapy alone (Figure 1). Survival for the six patients who
received supportive care only was universally poor (range
4-52 days, median 12 days).
Patients who were able to walk at the start of treatment
for SCC had somewhat longer survival than those who were
unable to walk, but this did not achieve statistical signifi-
cance (P= 0.11, Figure 2). There was, however, a highly
significant improvement in survival for those walking after
completion of treatment compared with those who were not
(Figure 3, P = 0.001). This difference was equally apparent in
both the radiotherapy and surgery groups. The other signifi-
cant predictor of survival was time to SCC from diagnosis of
primary breast cancer, with those developing SCC after 3 or
more years showing improved survival post SCC (Figure 4).
No other factors were identified which predicted survival
following cord compression including number of metastatic
sites.
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Discussion
Most reports of spinal cord compression complicating meta-
static cancer have included patients with a variety of different
tumour types (Constans et al., 1983; White et al., 1971;
Findlay, 1984). Risk factors for the development of SCC and
appropriate treatment for SCC are likely to differ between
tumour types, because of wide variations in the natural his-
I 43 tory of different cancers and in their responsiveness to
different treatments. Recent studies of SCC in patients with
4 5 small cell lung cancer have, for example, shown that the risk
of SCC developing is associated with abnormal spinal bone
scintigraphy and the presence of cerebral metastases (Gold-
compression by man et al., 1989). If in addition, there is a history of back
pain, the risk of SCC rises. Constans et al. (1983) reported
the outcome for patients referred to two neurosurgical cen-
tres for management of spinal cord compression secondary to
malignancy. The mean survival for 153 patients with breast
cancer in that study (5 months) was similar to that of
patients receiving definitive surgery or radiotherapy in our
study (7 months).
In the current study, a total of 70 patients with proven
SCC from metastatic breast cancer were identified. Over this
period 1,684 patients were seen in the Breast Unit with
metastatic disease, giving an incidence of cord compression
ofjust over 4%. One of the major aims of the study was to
look for factors which might assist in identification of a
subgroup of patients at particularly high risk of developing
ng N - 22 SCC. If such a group can be identified specific advice could
be given concerning early warning signs of impending cord
4 5 compression, so that more patients might be treated while
still ambulant. The potential importance of such a strategy is
highlighted by the findings that 96% of patients who present-
compression by ed while still ambulant maintained their ability to walk,
whereas only 45% of those who had lost the ability of walk972 M.E. HILL et al.
regained this capacity following treatment. An important
finding was that the large majority of patients had had
symptoms for more than a week before presentation with
cord compression. This suggests that a targeted information
programme might promote earlier diagnosis of this complica-
tion.
No features at the time of diagnosis of primary breast
cancer were identified which helped to predict subsequent
development of SCC. Only two patients presented with SCC
as the first evidence of relapse. This suggests that it is
unnecessary to warn patients in first remission of this possi-
bility. Sixty-five (93%) of the patients were known to have
bone metastases (though not necessarily spinal metastases)
before the onset of any neurological deficit. Patients with any
bone metastases might be advised to report the development
of back pain as soon as possible and not to wait for their
next routine follow up appointment. Those with known
spinal metastases should, in particular, be asked to report
worsening back pain, leg weakness, sensory change or
sphincter disturbance urgently.
All patients with SCC in this study received dexametha-
sone up to a maximum dose of 16 mg/day. Dexamethasone
was not, however, routinely prescribed for patients undergo-
ing radiotherapy for pain control, and 11 patients developed
SCC whilst receiving such treatment. The number of patients
who received radiotherapy for painful spinal metastases at
Guy's hospital during the study period is not known, but
would have been large. The role of prophylactic dexametha-
sone for such patients cannot be evaluated from these data
alone, but such treatment may be advisable provided there
are no contraindications.
There is little evidence from clinical trials that steroids are
beneficial in cases of established SCC, and where improve-
ment does occur it is generally transient (Byrne, 1992).
Steroids have, however, been shown to be effective in an
experimental animal model (Ushio et al., 1977) and other
preclinical studies have demonstrated a dose-related benefit
(Delattre et al., 1989).
The finding of this study also indicate that patients who
have received spinal radiotherapy for pain control are at
substantial risk of subsequent SCC. Surveillance of patients
at high risk of developing SCC by Magnetic Resonance
Imaging would be feasible, but the value of such screening
for early cord compression would need to be assessed pros-
pectively.
The second aim of this study was to examine factors which
determine functional outcome and survival after SCC.
Ambulatory ability at the start of treatment was, not surpris-
ingly, the main predictor of the ability to walk following
treatment. This echoes the findings of a previous study in
breast cancer (Harrison et al., 1985), a retrospective review of
several cancer types (Stark et al., 1982) and a recent review
of SCC in prostate cancer (Zelefsy et al., 1992). No differ-
ences were observed in the efficacy of radiotherapy and
decompressive surgery, but it should be noted that the selec-
tion of treatment was not randomised. In a literature review
of 1,800 cases (Findlay, 1983), treatment of ambulant
patients with laminectomy followed by radiotherapy resulted
in 67% of patients remaining ambulant, but only 48% of
those treated by laminectomy alone did so. Those treated by
radiotherapy alone, however, had a 79% chance of remaining
ambulant. Radiotherapy also gave superior results in patients
who were paraparetic on presentation. Taken with the results
of the current study, these findings lend weight to the concept
that radiotherapy for malignant spinal cord compression is
certainly no worse than surgery. Two other retrospective
studies (Posner, 1987; Siegal & Siegal, 1989) and one small
prospective study (Young et al., 1980) have failed to demon-
strate a difference in outcome between radiotherapy alone
and laminectomy followed by radiotherapy. This finding is in
contrast to older studies in which surgery followed by radio-
therapy was recommended as the treatment ofchoice (Bansal
et al., 1967; Brady et al., 1957). Surgery does, however, have
a role in certain situations, specifically when compression
occurs at a previously irradiated level and when neurological
deterioration occurs during radiotherapy despite large doses
of corticosteroids (Posner, 1987; Siegal & Siegal, 1989). Fur-
ther indications include symptomatic spinal instability and
intractable pain and clearly careful patient selection is essen-
tial (Harrington, 1984).
Survival following SCC was generally short (median 4
months). Twenty-two (32%) patients survived for more than
6 months, of whom 12 (17%) were alive for 1 year or more
following SCC. There was no difference in survival between
those treated by primary surgery or radiotherapy, although
all those judged to be too unwell for definitive treatment died
within 2 months. Ambulatory status prior to treatment did
not significantly influence survival, although it did predict for
ability to walk after treatment. Walking ability post therapy
did, however, predict survival with markedly superior sur-
vival in the walking group (P<0.001). The only known
factor prior to SCC which was found to predict survival
significantly was time from first diagnosis of breast cancer to
development of SCC. Those with early onset (<3 years)
fared worse (P = 0.04) but the effect was relatively small.
In conclusion, this study has confirmed the incidence of
spinal cord compression in breast cancer, and the grim prog-
nosis it carries whatever the treatment. We have shown that
nearly all patients have warning symptoms for a week or
more, and that all are likely to have manifest bone metas-
tases prior to developing SCC. The results suggest that ear-
lier diagnosis and intervention may improve outcome. In
view of the potential morbidity and hospitalisation that may
result from surgery for patients with only a very limited life
expectancy, we prefer to use radiotherapy and steroids for
the management of uncomplicated cases.
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